Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review ...
Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that the High Court of Ireland (the "Irish High Court") has made...
Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced the publication of findings from a retrospective chart review...
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced the publication of findings from a retrospective medical...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a...
Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that its Plan of Reorganization (the "Plan") has been confirmed...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, announced that it received a score of 100 on the Human Rights Campaign...
Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA, a Phase 1/2a...
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective medical chart review studies...
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results from a retrospective medical chart review study...
Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached an agreement with the Official Committee of...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing...
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that its Specialty Generics division has been recognized as...
Mallinckrodt plc, a global biopharmaceutical company, today announced that employees Tanya Hill, Executive Director, Commercial Strategy and Brand...
Ein Projekt, das die immunmodulatorischen Effekte der extrakorporalen Photopherese-Therapie (ECP) durch körpereigene Zellen analysieren wird, hat den ...
Un projet qui analysera les effets immunomodulateurs de la thérapie par photophorèse extracorporelle (ECP) par le biais de cellules innées a remporté ...
Un proyecto que va a analizar los efectos inmunomoduladores de la terapia de fotoforesis extracorpórea (ECP) por medio de las células innatas ha...
Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien...
Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the...
Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.